Cargando...
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC...
Gardado en:
| Publicado en: | Int J Mol Sci |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7700698/ https://ncbi.nlm.nih.gov/pubmed/33266366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21228828 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|